Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors
Kashif Rahim,Muhammad Shan,Ihtisham Ul Haq,Muhammad Nawaz,Sajida Maryam,Mansour Alturki,Abdulaziz Al Khzem,Kamel Metwally,Simona Cavalu,Saleh Alqifari,Galal Yahya
DOI: https://doi.org/10.2147/jir.s442106
IF: 4.5
2024-03-24
Journal of Inflammation Research
Abstract:Kashif Rahim, 1 Muhammad Shan, 2 Ihtisham Ul Haq, 3– 5 Muhammad Naveed Nawaz, 2 Sajida Maryam, 3, 4 Mansour S Alturki, 6 Abdulaziz H Al Khzem, 6 Kamel Metwally, 7 Simona Cavalu, 8 Saleh F Alqifari, 9 Galal Yahya 10 1 School of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, People's Republic of China; 2 Department of Microbiology, Cholistan University of Veterinary and Animal Sciences, Bahawalpur, Punjab, Pakistan; 3 Department of Physical Chemistry and Technology of Polymers, Silesian University of Technology, Gliwice, Poland; 4 Joint Doctoral School, Silesian University of Technology, Gliwice, 44-100, Poland; 5 Programa de Pós-graduação em Inovação Tecnológica, Universidade Federal de Minas Gerais, Belo Horizonte, MG, 31270-901, Brazil; 6 Department of Pharmaceutical Chemistry, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, 34212, Saudi Arabia; 7 Department of Medicinal Chemistry, Faculty of Pharmacy, University of Tabuk, Tabuk, 71491, Saudi Arabia; 8 Faculty of Medicine and Pharmacy, University of Oradea, Oradea, 410073, Romania; 9 Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, 71491, Saudi Arabia; 10 Department of Microbiology and Immunology, Faculty of Pharmacy, Zagazig University, Al Sharqia, 44519, Egypt Correspondence: Kashif Rahim, School of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, People's Republic of China, Email Saleh F Alqifari, Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, 71491, Saudi Arabia, Email DPP4 (Dipeptidyl-peptidase 4) a versatile protease, emerges as a prominent player in soluble and membrane-bound forms. Its heightened expression has been intimately linked to the initiation and severity of diverse autoimmune diseases, spanning rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis (SSc), inflammatory bowel disease, autoimmune diabetes, and even SARS-CoV-2 infection. Operating as a co-stimulator of T cell activity, DPP4 propels T cell proliferation by binding adenosine deaminase (ADA), thereby augmenting the breakdown of adenosine—an influential inhibitor of T cell proliferation. However, the discovery of a wide range of DPP4 inhibitors has shown promise in alleviating these diseases' signs, symptoms, and severity. The available DPP4 inhibitors have demonstrated significant effectiveness in blocking DPP4 activity. Based on the characterization of their binding mechanisms, three distinct groups of DPP4 inhibitors have been identified: saxagliptin, alogliptin, and sitagliptin, each representing a different class. Elevated levels of angiotensin-converting enzyme 2 (ACE2) expression are associated with producing various coronavirus peptidases. With its anti-inflammatory properties, Sitagliptin may assist COVID-19 patients in preventing and managing cytokine storms. This comprehensive review delves into the burgeoning realm of DPP4 inhibitors as therapeutic interventions for diverse autoimmune diseases. With a discerning focus on their efficacy, the investigation sheds light on their remarkable capacity to alleviate the burdensome signs and symptoms intricately linked to these conditions. Keywords: autoimmune diseases, DPP4 inhibitors, inflammatory disorders, MERS-CoV, diabetes mellitus, COVID-19 Dipeptidyl-peptidase 4 (DPP4), also known as CD26, is a significant enzyme belonging to the SC serine peptidase clan, specifically within its subfamily 9b. The structure and function of DPP4 are characterized by a distinct enzymatic triad. This triad is composed of three amino acids: Serine (Ser), Aspartic acid (Asp), and Histidine (His). These are crucial for the enzyme's activity and are situated within a specific structural motif known as the a/b-hydrolase loop. 1 This combination of Ser, Asp, and His in DPP4's active site is what sets it apart from other similar enzymes. For comparison, the catalytic triad in enzymes like chymotrypsin, another well-known serine protease, comprises Histidine (His), Aspartic acid (Asp), and Serine (Ser). Although the components are the same, the order and specific arrangement within the protein structure differ significantly, leading to differences in their enzymatic functions. DPP4 was first identified in 1966. Since its discovery, DPP4 has been extensively studied due to its role in various physiological processes and its implications in medical conditions like diabetes and cancer. As CD26, it is also known for its role as a cell surface protein involved in immune regulation and signal transduction. 2 DPP4 pre -Abstract Truncated-
immunology